September 25, 2021 Chula Radio plus has released new soundcloud with the topic of “Emerging Infectious Diseases & Search for New Vaccines”

Emerging infectious disease is defined as the diseases whose incidence in humans has increased in the past two decades or threatens to increase in the near future. They can be either newly discovered diseases or re-emerged diseases, but the underline is these diseases are capable of spreading very quickly beyond national boundaries and of becoming major public and global concerns as potential causes of worldwide pandemic. It has been found that there has been an increase in the emergence of new infectious diseases, as around 30 new diseases have been identified in recent decades. It is believed that the fight against these infectious diseases is the development of vaccines against new viruses. Fortunately, with the gradual advancement of medical technology, researchers worldwide are developing new techniques of vaccine production to enhance its efficiency. Guests of this episode are Prof. Dr. Thiravat Hemachudha, head of Thai Red Cross Emerging Infectious Diseases – Health Science Center, Chulalongkorn Hospital, and Asst. Prof. Dr. Suthira Taychakhoonavudh of Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University. Dr. Suthira is also chief executive and co-founder of Baiya Phytopharm, which is developing new kinds of vaccines.


About Baiya Phytopharm
Baiya Phytopharm is a clinical-stage biopharmaceutical company, focused on strengthening health security for all people using the BaiyaPharming platform protein for therapeutics and vaccines. Baiya Phytopharm’s plant-based technology is a cutting-edge solution that is quick, simple, and scalable, aiming to replace biotech’s fermenter with plants. Our team combines deep technology expertise in plant biotech, pharmaceutical production professions and clinical development capabilities to create biologics candidates with high unmet medical needs of the ASIA-Pacific region. We have generated a broad proprietary portfolio of candidates including monoclonal antibodies for cancer or infectious disease and new vaccines for neglected tropical diseases.